bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

1

The global population of SARS-CoV-2 is composed of six major subtypes

2
3

Ivair José Morais Júniora, Richard Costa Polveirob, Gabriel Medeiros Souzac, Daniel Inserra

4

Bortolinc, Flávio Tetsuo Sassakid, Alison Talis Martins Limac*

5
6

a

7

b

8

c

9

Brazil

Departamento de Fitopatologia/Universidade de Brasília, Brasília, DF 70910-900, Brazil
Departamento de Veterinária/Universidade Federal de Viçosa, Viçosa, MG 36570-900, Brazil

Instituto de Ciências Agrárias/Universidade Federal de Uberlândia, Uberlândia, MG 38410-337,

10

d

11

Brazil

Instituto de Biotecnologia/Universidade Federal de Uberlândia, Monte Carmelo, MG 38500-000,

12
13

*E-mail: atmlima@ufu.br

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Abstract
The World Health Organization characterized the COVID-19 as a pandemic in March 2020, the second
pandemic of the 21st century. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a
positive-stranded RNA betacoronavirus of the family Coronaviridae. Expanding virus populations, as
that of SARS-CoV-2, accumulate a number of narrowly shared polymorphisms imposing a
confounding effect on traditional clustering methods. In this context, approaches that reduce the
complexity of the sequence space occupied by the SARS-CoV-2 population are necessary for a robust
clustering. Here, we proposed the subdivision of the global SARS-CoV-2 population into sixteen welldefined subtypes by focusing on the widely shared polymorphisms in nonstructural (nsp3, nsp4, nsp6,
nsp12, nsp13 and nsp14) cistrons, structural (spike and nucleocapsid) and accessory (ORF8) genes.
Six virus subtypes were predominant in the population, but all sixteen showed amino acid
replacements which might have phenotypic implications. We hypothesize that the virus subtypes
detected in this study are records of the early stages of the SARS-CoV-2 diversification that were
randomly sampled to compose the virus populations around the world, a typical founder effect. The
genetic structure determined for the SARS-CoV-2 population provides substantial guidelines for
maximizing the effectiveness of trials for testing the candidate vaccines or drugs.

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

32

Main

33

In December 2019, a local pneumonia outbreak of initially unknown etiology was detected in

34

Wuhan (Hubei, China) and quickly determined to be caused by a novel coronavirus1, named Severe

35

acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2 and the disease as COVID-193. SARS-

36

CoV-2 is classified in the family Coronaviridae, genus Betacoronavirus, which comprises enveloped,

37

positive stranded RNA viruses of vertebrates2. Two-thirds of SARS-CoVs genome is covered by the

38

ORF1ab, that encodes a large polypeptide which is cleaved into 16 nonstructural proteins (NSPs)

39

involved in replication-transcription in vesicles from endoplasmic reticulum (ER)-derived

40

membranes4,5. The last third of the virus genome encodes four essential structural proteins: spike (S),

41

envelope (E), membrane (M), nucleocapsid (N) and several accessory proteins that interfere with the

42

host innate immune response6.

43

Populations of RNA viruses evolve rapidly due to their large population sizes, short generation

44

times, and high mutation rates, this latter being a consequence of the RNA-dependent RNA

45

polymerase (RdRP) which lacks the proofreading activity7. In fact, virus populations are composed of

46

a broad spectrum of closely related genetic variants resembling one or more master sequences8–10.

47

Mutation rates inferred for SARS-CoVs are considered moderate11,12 due to the independent

48

proofreading activity13. However, the large SARS-CoV genomes (from 27 to 31 kb)14 provide to them

49

the ability to explore the sequence space15. In order to better understand the diversification of SARS-

50

CoV-2 genomes during the pandemics (from December 2019 to March 25, 2020), we applied a simple,

51

but robust approach to reduce the complexity of the sequence space occupied by the virus population

52

by detecting its widely shared polymorphisms.

53

The 767 SARS-CoV-2 genomes with high sequencing coverage obtained from GISAID

54

(https://www.gisaid.org/) and GenBank were clustered into 593 haplotypes (Table S1). We conducted

55

a fine-scale sequence variation analysis on the 593 genomes-containing alignment by calculating the

56

nucleotide diversity (π) using a sliding window and step size of 300 and 20 nucleotides, respectively

57

(multiple sequence alignments generated in this study are available from the authors upon request).

58

Such an approach allows to identify genomic regions of increased genetic variation from polymorphic

59

sites harboring two or more distinct nucleotide bases. Noticeably, one or more large clusters of closely

60

related sequences, when analyzed by this approach, show locally increased nucleotide diversity. We

61

observed a contrasting distribution of the genetic variation across the full-length genomes of SARS-

62

CoV-2 (Fig. 1) with eight segments showing increased genetic variation, arbitrarily defined as

2

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

63

nucleotide (nt) segments with π ≥ 0.001. Seven out of eight segments (S) had about 280 nucleotides

64

in length, corresponding approximately to the size of a single sliding window, except the S10 whose

65

length was equivalent to two sliding windows (600 nt). To further investigate the diversification of

66

segments with contrasting content of genetic variability, we constructed maximum likelihood (ML)

67

phylogenetic trees and analyzed the diversification patterns of eight segments with higher (S2, 4, 6, 8,

68

10, 12, 14 and 16), and nine with lower (S1, 3, 5, 7, 9, 11, 13, 15 and 17) content of genetic variation,

69

respectively.

70

Although the data set was composed of hundreds of SARS-CoV-2 genomes sampled from

71

around the world, in the S2-based tree we observed two clusters (Fig. S1a). Markedly, each cluster

72

was composed of very closely related, if not identical, sequences. Therefore, the increased content of

73

genetic variation at the S2 was a result of the inter-cluster sequence comparisons. Similar results were

74

obtained for the other seven ML-trees based on segments with increased genetic variation (Fig. S1b -

75

h). In contrast, the ML-trees based on segments with lower content of genetic variation did not show

76

a consistent number of well-defined clusters (Fig. S2).

77

We mapped the polymorphic sites in segments with increased content of genetic variation

78

responsible for the segregation of ML-trees into two well-defined clusters (Table 1). Only a few (from

79

one to three) nt positions with polymorphisms shared by a number of SARS-CoV-2 genomes could be

80

identified within each segment with increased genetic variation. These polymorphisms were

81

henceforth referred to as ‘widely shared polymorphisms’ (WSPs), while the remaining nt positions in

82

virus genomes were designed as ‘non widely shared polymorphisms’ (nWSPs).

83

We compared the topologies of the seventeen ML-trees by computing their pairwise distances

84

followed by a multivariate analysis to group similar trees (Fig. 2). The seventeen trees were subdivided

85

into seven groups, the largest one containing those nWSPs-containing segments-based trees (S1, 3, 5,

86

7, 9, 11, 13, 15 and 17; Fig. 2, Group 7). Given the low content of genetic variation in these segments,

87

the resulting trees were poorly resolved suggesting that such regions represent a wide mutant spectrum

88

of narrowly shared polymorphisms. It is important to note that there are minor clusters in nWSPs-

89

containing segments-based ML-trees, e.g., in those for S1, S13 and S17. This is a consequence of our

90

conservative threshold in which we focused on segments with π ≥ 0.001. S1, S13 and S17 also show

91

locally increased genetic variation with π higher than 0.0005 but lower than 0.001. For example,

92

stretches 889 - 1,169; 1,409 - 1,509 (within the S1); 25,403 - 25,693 (S13); 29,538 - 29,610 (S17)

93

(Fig. 1).

3

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

94

The S2, S8 and S12-based ML-trees (Fig. 2, Group 1) were considerably congruent and the

95

nucleotides at their WSPs tended to co-segregate (UUG or CCA, Table 1), which results into two

96

major subtypes of SARS-CoV-2. Reciprocally, the incongruency among the S4, 6, 10, 14 and 16-

97

based trees (Fig. 2, Groups 2-6) suggests the segregation of nucleotides at their WSPs, which increases

98

the possible combinations of virus genotypes.

99

Therefore, our approach reduced the complexity of the sequence space occupied by the SARS-

100

CoV-2 genomes and provided a robust clustering solution based on the combination of 12 WSPs

101

(Table 1) to identify the major viral genotypes spread worldwide (Table 2 and Table S2). The global

102

population of SARS-CoV-2 is structured into six major subtypes (I - VI), comprising 578 out of 593

103

(about 97.5%) isolates analyzed in this study. The Subtype I (N=132) was represented by the

104

combination of the most frequent nucleotides at all WSPs, i.g., the canonical genotype:

105

CCGCCACAUGGG. The SARS-CoV-2 reference isolate (GISAID accession ID: EPI_ISL_402124,

106

GenBank accession: MN908947) is a representative member of this subtype. Subtype IV (N=91) was

107

represented by the combination of the most frequent nucleotides at eleven out of 12 WSPs

108

(CCUCCACAUGGG; the most frequent nucleotides at each WSP are highlighted in bold and

109

underlined). Subtypes V (N=74, CUGCCACACGGG), II (N=122, UCGUCACGUGGG), III

110

(N=101, CUGCUGUACGGG) and VI (N=58, UCGUCACGUAAC) were represented by the

111

combination of the most frequent nucleotides at ten, nine, seven and six out of 12 WSPs, respectively.

112

It is important to emphasize that the contrasting sample sizes (Subtypes I - VI vs. VII - XVI) are not

113

necessarily associated with fitness variation and might be due to a sampling bias. For example, the

114

three isolates composing the Subtype VIII showed a genotype (CUGCCAUACGGG) very similar to

115

that of the canonical reference isolate. In addition, even though our data set was composed exclusively

116

by genomes with high sequencing coverage, we cannot rule out that the virus subtypes X to XVI,

117

which were represented by a single genome might be a consequence of poor sampling or sequencing

118

errors.

119

The phylogenetic tree depicting all 593 SARS-CoV-2 haplotypes (Fig. 3) showed some

120

geographical structure with two clusters: a smaller one comprised of isolates mostly sampled from

121

Western hemisphere (Subtypes II, VI, IX, X and XI) and a larger one whose isolates were sampled

122

from Western and Eastern hemispheres (I, III, IV, V, VII, VIII, XII, XIII, XIV, XV and XVI).

123

We hypothesize that our clustering method for the SARS-CoV-2 population could involve at

124

some extent a biological context. Nine out of 12 WSPs led to amino acid replacements (Table 2), e.g.,

4

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

125

the WSP nsp6-[111] in nine SARS-CoV-2 subtypes led to a leucine at the aa residue#37 of the protein

126

and a phenylalanine in seven other subtypes. NSP6 is an integral membrane protein that interferes in

127

the autophagosome formation during the SARS-CoV infection. Additionally, in yeast two-hybrid

128

experiments, NSP6 has been shown to interact with NSP316. Some evidence demonstrates that NSP6

129

protein limits the expansion of autophagosomes or, alternatively, might remove host proteins involved

130

in inhibition of viral replication by activating autophagy from the ER17.

131

The WSP nsp12-[967] resulted in a proline in eleven subtypes of SARS-CoV-2 and a leucine

132

in others five subtypes at the aa residue #323 of the NSP12 (RNA-dependent RNA polymerase, RdRP)

133

protein. It is located at the Interface domain of RdRP of SARS-CoV-2, which is responsible for the

134

connection between the nidovirus RdRP-associated nucleotidyltransferase domain (NiRAN) and the

135

“Right hand” polymerase domain18. The S protein mediates viral entry into host cells by first binding

136

to a receptor, angiotensin-converting enzyme 2 (ACE2), through the receptor-binding domain (RBD)

137

in the S1 subunit and then fusing the viral and host membranes through the S2 subunit19–22. Sites of

138

glycosylation are important for S protein folding23, affecting priming by host proteases24 and might

139

modulate antibody recognition25,26. The WSP S-[1,841] resulted in a glycine and an aspartate at the aa

140

residue#614 of the S protein in six and ten subtypes of SAR-CoV-2, respectively. The replacement

141

was mapped in the intermediate region between the S1 and S2 subunits. This WSP is near a

142

glycosylation site (N616CT)27.

143

The WSP ORF8-[251] involved a non-synonymous mutation at the codon#84 encoding for

144

leucine and serine in nine and seven subtypes, respectively. The SARS-CoV ORF8 encodes for an

145

ER-associated protein that induces the activation of ATF6, and this latter is an ER stress-regulated

146

transcription factor that stimulates the production of chaperones28. In addition, the ORF8 protein has

147

been demonstrated to induce apoptosis29. In SARS epidemics, the ORF8 from different coronaviruses

148

was targeted by a number of mutations and recombination events during transmission from animals to

149

humans30.

150

Three WSPs mapped in the N gene led to two amino acid replacements at residues#203 and

151

#204. The multifunctional N protein is composed of three domains31, two of which are structurally

152

independent: the N-terminal domain (NTD) and the C-terminal domain (CTD). Both amino acid

153

replacements were mapped in an intermediary domain referred to as the linker region (LKR), a

154

positively charged serine-arginine-rich region. As an intrinsically disordered region (IDR) it allows

155

the independent folding of the NTD and CTD32 and is also functionally implicated in RNA binding

5

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

156

activity31. Key determinants of the interaction between the N and NSP3 proteins were also mapped at

157

the LKR33. The SARS-CoV N protein is also responsible for an antigenic response in humans

158

predominantly involving the immunoglobulin G34. Although the host biological factors involved in

159

the response to SARS-CoV-2 infection are still poorly known, the existence of distinct virus subtypes,

160

all of them exhibiting amino acid replacements, could alter important aspects of COVID-19.

161

We hypothesized that in the early stages of the SARS-CoV-2 epidemics, due to the rapid virus

162

population expansion, a number of genetic variants might have arisen followed by a spread of non-

163

representative sampling of variants to other countries and continents, i.g., a founder effect. We argue

164

that the virus subtypes and their associated WSPs detected in this study would be records of

165

diversification in these early stages of the epidemics after transmission from animal to humans. After

166

the virus introduction in a given geographic region, a number of unique or narrowly shared mutations

167

is accumulated, however, most of them reduce the fitness and are removed by purifying selection in a

168

medium to long term evolutionary scale, tending to a decreasing genetic variability8.

169

We propose a classification into at least sixteen distinct subtypes of SARS-CoV-2, six of them

170

accounting for more than 97% of the sampled isolates from around the world. Such classification

171

might guide the validation of candidate vaccines or drugs for the widest range of virus subtypes. In

172

this context, our clustering solution provides a robust approach to effectively reduce the complexity

173

of the mutant spectrum composed of closely related SARS-CoV-2 genomes focusing on WSPs.

174

Additionally, through the exhaustive sequencing, it would be possible to identify novel virus subtypes

175

and follow the evolutionary dynamics of the SARS-CoV-2 population during the adaptive process

176

imposed by the human host.

6

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

Table 1 | Characterization of the WSPs detected in genomes of SARS-CoV-2

177
178

Segment
ID

Segment
position*
(begin - end)

WSPs†

nt mutation
(# isolates)

Position
in the
codon

#codon

Amino acid

S2

2,872 - 3,152

nsp3-[318]

U (184) / C (409)

Third

106

Phenylalanine/Phenylalanine

S4

8,612 - 8,892

nsp4-[228]

U (183) / C (410)

Third

76

Serine/Serine

S6

10,932 - 11,192

nsp6-[111]

C (1) / U (99) / G (493)

Third

37

Phenylalanine/Phenylalanine/Leucine

S8

14,232 - 14,512

nsp12-[967]

U (184) / C (409)

Second

323

Leucine/Proline

nsp13-[1,511]

U (101) / C (492)

Second

504

Leucine/Proline

nsp13-[1,622]

G (101) / A (492)

Second

541

Cysteine/Tyrosine

nsp14-[21]

U (105) / C (488)

Third

7

Leucine/Leucine

S10

S12

23,243 - 23,523

S-[1,841]

G (185) / A (408)

Second

614

Glycine/Aspartate

S14

27,977 - 28,258

ORF8-[251]

C (184) / U (409)

Second

84

Serine/Leucine

N-[608]

A (60) / G (533)

Second
203

Lysine/Arginine

N-[609]

A (60) / G (533)

Third

N-[610]

C (60) / G (533)

First

204

Glycine/Arginine

S16

179
180

17,573 -18,173

28,718 - 28,998

*
†

Relative to the multiple sequence alignment constructed for full-length genomes
Widely Shared Polymorphisms (WSPs) are conventionally indicated by cistron/gene-[nt position within the cistron or gene]

7

181
182

Table 2 | Unique genotypes of SARS-CoV-2 based on 12 WSPs and their associated amino acid replacements

SUBTYPES

I
II
III
IV
V
VI
VII
VIII
IX
X
XI
XII
XIII
XIV
XV
XVI
183
184
185
186
187

N

*

132
122
101
91
74
58
3
3
2
1
1
1
1
1
1
1

S2£
nsp3
#318

S4
nsp4
#228

S6
nsp6
#111

S8
nsp12
#967

nsp14
#21

S12
S
#1,841

S14
ORF8
#251

#608

S16
N
#609

nsp13
#1511
#1622

†

#610

C [Ser]

G [Leu]

C [Pro]

C [Pro]

A [Tyr]

C [Leu]

A [Asp]

U [Leu]

G [Arg]

G [Arg]

G [Arg]

U [Phe]

C [Ser]

G [Leu]

U [Leu]

C [Pro]

A [Tyr]

C [Leu]

G [Gly]

U [Leu]

G [Arg]

G [Arg]

G [Arg]

C [Phe]

U [Ser]

G [Leu]

C [Phe]

C [Ser]

U [Phe]

C [Pro]

U [Leu]

G [Cys]

U [Leu]

C [Pro]

C [Pro]

A [Tyr]

C [Leu]

A [Asp]

C [Ser]

G [Arg]

G [Arg]

G [Arg]

A [Asp]

U [Leu]

G [Arg]

G [Arg]

G [Arg]

C [Phe]

U [Ser]

G [Leu]

C [Pro]

C [Pro]

A [Tyr]

C [Leu]

A [Asp]

C [Ser]

G [Arg]

G [Arg]

G [Arg]

U [Phe]

C [Ser]

G [Leu]

U [Leu]

C [Pro]

A [Tyr]

C [Leu]

G [Gly]

U [Leu]

A [Lys]

A [Lys]

C [Gly]

C [Phe]

U [Ser]

U [Phe]

C [Pro]

C [Pro]

A [Tyr]

C [Leu]

A [Asp]

C [Ser]

G [Arg]

G [Arg]

G [Arg]

C [Phe]

U [Ser]

G [Leu]

C [Pro]

C [Pro]

A [Tyr]

U [Leu]

A [Asp]

C [Ser]

G [Arg]

G [Arg]

G [Arg]

U [Phe]

C [Ser]

U [Phe]

U [Leu]

C [Pro]

A [Tyr]

C [Leu]

G [Gly]

U [Leu]

A [Lys]

A [Lys]

C [Gly]

U [Phe]

C [Ser]

U [Phe]

U [Leu]

C [Pro]

A [Tyr]

C [Leu]

G [Gly]

U [Leu]

G [Arg]

G [Arg]

G [Arg]

U [Phe]

C [Ser]

G [Leu]

C [Pro]

C [Pro]

A [Tyr]

C [Leu]

G [Gly]

U [Leu]

G [Arg]

G [Arg]

G [Arg]

C [Phe]

U [Ser]

C [Phe]

C [Pro]

C [Pro]

A [Tyr]

C [Leu]

A [Asp]

C [Ser]

G [Arg]

G [Arg]

G [Arg]

C [Phe]

C [Ser]

G [Leu]

C [Pro]

C [Pro]

A [Tyr]

C [Leu]

A [Asp]

C [Ser]

G [Arg]

G [Arg]

G [Arg]

C [Phe]

U [Ser]

G [Leu]

C [Pro]

C [Pro]

A [Tyr]

C [Leu]

G [Gly]

C [Ser]

G [Arg]

G [Arg]

G [Arg]

C [Phe]

C [Ser]

U [Phe]

U [Leu]

C [Pro]

A [Tyr]

C [Leu]

A [Asp]

U [Leu]

G [Arg]

G [Arg]

G [Arg]

C [Phe]

C [Ser]

U [Phe]

C [Pro]

C [Pro]

A [Tyr]

U [Leu]

A [Asp]

U [Leu]

G [Arg]

G [Arg]

G [Arg]

C [Phe]

S10

*

Sample size
Segment containing the WSP
#
Nucleotide position
†
Nucleotide base and the encoded amino acid residue
£

8

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

188

Figure legends

189

Fig. 1 | Mean pairwise number of nucleotide differences per site (nucleotide diversity, π) calculated

190

using a sliding window of 300 nucleotides across the multiple sequence alignment for full-length

191

genomes of SARS-CoV-2. The red dashed line at π = 0.001 represents an arbitrary threshold to

192

subdivide the segments (S) with increased (S2, 4, 6, 8, 10, 12, 14 and 16) and lower (S1, 3, 5, 7,

193

9, 11, 13,15 and 17) content of genetic variation. The SARS-CoV-2 genome organization is

194

represented on top of the plot.

195

Fig. 2 | Multidimensional Scaling (MDS) visualization of tree distances based on Kendall Colijn

196

metrics (λ = 0). The seventeen ML-trees (each one with 593 tips) are represented as dots. Seven

197

groups of trees are represented with different colors. The WSP-containing segments-based trees

198

(S2, S8 and S12) formed six groups (1 - 6 are indicated in blue, red, green, orange, purple and

199

brown, respectively). All nWSPs-containing segments-based ML-trees formed a single group

200

indicated in pink.

201

Fig. 3 | Maximum likelihood phylogenetic tree based on 12 WSPs detected across the SARS-CoV-

202

2 genomes.

9

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

203

Methods

204

A total of 1,137 full-length genomes of SARS-CoV-2 sampled from December 2019 to

205

March 25, 2020 (at 2:30 pm) were obtained from Genbank35 and GISAID36 (Table S1). Only

206

genomes with high sequencing coverage, intact ORFs (no frameshifts, except that of nsp12 cistron)

207

and without any indeterminate nucleotide base (indicated by ‘N’s or ambiguous codes) totalizing

208

767 high quality full-length sequences were effectively analyzed in this study. We wish to

209

acknowledge all researchers that deposited the SARS-CoV-2 genomes in GISAID and/or GenBank

210

databases.

211

The genomic data set was aligned using MAFFT-FFT-NS-237. The calculation of the

212

average number of nucleotide differences per site (nucleotide diversity, π) was conducted in

213

DnaSP v.638 using a sliding window and step size of 300 and 20 nucleotides, respectively. Sites

214

with gaps alignment were not considered in analysis.

215

Maximum likelihood (ML) phylogenetic trees were constructed using RAxML39 under the

216

nucleotide substitution model General Time-Reversible with gamma distribution (GTRGAMMA).

217

The branch support for ML-trees based on 300-nucleotides and larger segments was assessed with

218

1,000 and 5,000 bootstrap replications, respectively. ML-trees were used in this study essentially

219

as a clustering method due to the weak phylogenetic signal in the data set. All phylogenetic trees

220

were edited using iTOL40. In order to assess the similarity among ML-tree topologies, we

221

computed all possible pairwise distances using the Kendall–Colijn metric41 followed by Principal

222

Coordinates Analysis (PCoA) using the package TREESPACE42 in R43.

223

The detection of polymorphic sites was conducted using PAUP* v. 4.044 and MEGA X45.

224

Those sites responsible for the segregation of the isolates into two clusters in the ML-trees were

225

referred to as “widely shared polymorphisms” (WSPs), while the remaining nt positions in the

226

virus genomes were designed as “non widely shared polymorphisms” (nWSPs). The WSPs were

227

conventionally indicated by cistron/gene name-[nt position within the cistron or gene]. We opted

228

by indicating the nt position within the cistron or gene due to their highly conserved lengths (no

229

gap was introduced during the construction of sequence alignments), in contrast to the full-

230

genomes whose 5’- and 3’-untranslated regions (UTRs) were highly variable in terms of length.

231
232

Data Availability: multiple sequence alignments and ML-phylogenetic trees generated in this

233

study are available from the authors upon request.

10

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279

References
1.
2.

3.
4.
5.

6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.

17.
18.
19.

20.

Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature
579, 265–269 (2020).
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The
species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and
naming it SARS-CoV-2. Nat. Microbiol. 5, (2020).
WHO. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11
February 2020. WHO website https://www.who.int/dg/speeches/detail/who-directo (2020).
Sawicki, S. G. & Sawicki, D. L. Coronavirus Transcription: A Perspective. in Current topics
in microbiology and immunology vol. 287 31–55 (2005).
de Wilde, A. H., Snijder, E. J., Kikkert, M. & van Hemert, M. J. Host Factors in Coronavirus
Replication. in Assessment & Evaluation in Higher Education vol. 37 1–42 (Springer
International Publishing, 2017).
Kim, D. et al. The architecture of SARS-CoV-2 transcriptome. (2020) doi:10.1088/17518113/44/8/085201.
Peck, K. M. & Lauring, A. S. Complexities of Viral Mutation Rates. J. Virol. 92, (2018).
Simmonds, P., Aiewsakun, P. & Katzourakis, A. Prisoners of war — host adaptation and its
constraints on virus evolution. Nat. Rev. Microbiol. 17, 321–328 (2019).
Domingo, E., Sheldon, J. & Perales, C. Viral Quasispecies Evolution. Microbiol. Mol. Biol.
Rev. 76, 159–216 (2012).
Domingo, E. & Perales, C. Viral quasispecies. PLoS Genet. 15, 1–20 (2019).
Zhao, Z. et al. Moderate mutation rate in the SARS coronavirus genome and its
implications. BMC Evol. Biol. 4, 1–9 (2004).
Gorbalenya, A. E., Enjuanes, L., Ziebuhr, J. & Snijder, E. J. Nidovirales: Evolving the
largest RNA virus genome. Virus Res. 117, 17–37 (2006).
Ma, Y. et al. Structural basis and functional analysis of the SARS coronavirus nsp14–nsp10
complex. Proc. Natl. Acad. Sci. 112, 9436–9441 (2015).
Knipe, D. M. & Howley, P. M. Fields virology. Viruses and the Lung: Infections and NonInfectious Viral-Linked Lung Disorders (2013).
Forni, D., Cagliani, R., Clerici, M. & Sironi, M. Molecular Evolution of Human
Coronavirus Genomes. Trends Microbiol. 25, 35–48 (2017).
Angelini, M. M., Akhlaghpour, M., Neuman, B. W. & Buchmeier, M. J. Severe Acute
Respiratory Syndrome Coronavirus Nonstructural Proteins 3, 4, and 6 Induce DoubleMembrane Vesicles. MBio 4, 1–10 (2013).
Cottam, E. M., Whelband, M. C. & Wileman, T. Coronavirus NSP6 restricts
autophagosome expansion. Autophagy 10, 1426–1441 (2014).
Gao, Y. et al. Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major
antiviral drug target. bioRxiv 2020.03.16.993386 (2020) doi:10.1101/2020.03.16.993386.
Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
Blocked by a Clinically Proven Protease Inhibitor. Cell 1–10 (2020)
doi:10.1016/j.cell.2020.02.052.
Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS
coronavirus. Nature vol. 426 450–454 (2003).

11

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325

21.

22.

23.
24.
25.
26.
27.
28.

29.

30.
31.

32.
33.
34.
35.
36.
37.

38.
39.
40.

Matsuyama, S. et al. Efficient Activation of the Severe Acute Respiratory Syndrome
Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2. J. Virol. 84, 12658–
12664 (2010).
Shulla, A. et al. A Transmembrane Serine Protease Is Linked to the Severe Acute
Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry. J. Virol. 85, 873–
882 (2011).
Rossen, J. W. A. et al. The Viral Spike Protein Is Not Involved in the Polarized Sorting of
Coronaviruses in Epithelial Cells †. J. Virol. 72, 497–503 (1998).
Yang, Y. et al. Two Mutations Were Critical for Bat-to-Human Transmission of Middle
East Respiratory Syndrome Coronavirus. J. Virol. 89, 9119–9123 (2015).
Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERSCoV spike antigen. Proc. Natl. Acad. Sci. U. S. A. 114, E7348–E7357 (2017).
Walls, A. C. et al. Unexpected Receptor Functional Mimicry Elucidates Activation of
Coronavirus Fusion. Cell 176, 1026–1039 (2019).
Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
Glycoprotein. Cell 180, 1–12 (2020).
Sung, S.-C., Chao, C.-Y., Jeng, K.-S., Yang, J.-Y. & Lai, M. M. C. The 8ab protein of
SARS-CoV is a luminal ER membrane-associated protein and induces the activation of
ATF6. Virology 387, 402–413 (2009).
Chen, C. et al. Open Reading Frame 8a of the Human Severe Acute Respiratory Syndrome
Coronavirus Not Only Promotes Viral Replication but Also Induces Apoptosis. J. Infect.
Dis. 196, 405–415 (2007).
Cui, J., Li, F. & Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev.
Microbiol. 17, 181–192 (2019).
Parker, M. M. & Masters, P. S. Sequence comparison of the N genes of five strains of the
coronavirus mouse hepatitis virus suggests a three domain structure for the nucleocapsid
protein. Virology 179, 463–468 (1990).
Huang, Q. et al. Structure of the N-Terminal RNA-Binding Domain of the SARS CoV
Nucleocapsid Protein. Biochemistry 43, 6059–6063 (2004).
Verheije, M. H. et al. The Coronavirus Nucleocapsid Protein Is Dynamically Associated
with the Replication-Transcription Complexes. J. Virol. 84, 11575–11579 (2010).
Leung, D. T. M. et al. Antibody Response of Patients with Severe Acute Respiratory
Syndrome (SARS) Targets the Viral Nucleocapsid. J. Infect. Dis. 190, 379–386 (2004).
Sayers, E. W. et al. GenBank. Nucleic Acids Res. 47, D94–D99 (2019).
Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data – from
vision to reality. Eurosurveillance 22, 2–4 (2017).
Katoh, K., Misawa, K., Kei-ichi, K. & Miyata, T. MAFFT: a novel method for rapid
multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 30, 3059–
3066 (2002).
Rozas, J. et al. DnaSP 6: DNA Sequence Polymorphism Analysis of Large Data Sets. Mol.
Biol. Evol. 34, 3299–3302 (2017).
Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large
phylogenies. Bioinformatics 30, 1312–1313 (2014).
Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v4: recent updates and new
developments. Nucleic Acids Res. 47, W256–W259 (2019).

12

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

326
327
328
329
330
331
332
333
334
335

41.
42.
43.
44.
45.

Kendall, M. & Colijn, C. Mapping Phylogenetic Trees to Reveal Distinct Patterns of
Evolution. Mol. Biol. Evol. 33, 2735–2743 (2016).
Jombart, T., Kendall, M., Almagro-Garcia, J. & Colijn, C. Treespace: Statistical exploration
of landscapes of phylogenetic trees. Mol. Ecol. Resour. 17, 1385–1392 (2017).
R Core Team. R: A language and environment for statistical computing. (2018).
Swofford, D. L. PAUP*: Phylogenetic Analysis Using Parsimony (*and Other Methods).
(2002) doi:10.1111/j.0014-3820.2002.tb00191.x.
Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: Molecular Evolutionary
Genetics Analysis across Computing Platforms. Mol. Biol. Evol. 35, 1547–1549 (2018).

13

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

336

Acknowledgments

337

This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível

338

Superior - Brasil (CAPES) - Finance Code 001. IJM and RCP were recipients of CNPq and CAPES

339

doctoral fellowships, respectively. DIB was the recipient of a FAPEMIG master fellowship. We

340

wish to acknowledge all researchers that deposited the SARS-CoV-2 genomes in GISAID and/or

341

GenBank databases.

342
343

Author Contributions

344

ATML designed the bioinformatics analyses. IJM, ATML, RCP, GMS, DIB and FTS conducted

345

the analyses. ATML, IJM, RCP and FTS analyzed data and results. IJM, RCP, FTS and ATML

346

wrote the manuscript. All authors contributed to the content and writing of the Supplementary

347

Information.

348
349

Competing interest declaration

350

The authors declare that they have no competing interests.

351
352

Materials & Correspondence

353

Alison Talis Martins Lima

354
355

Additional information

356

Supplementary information is available for this manuscript.

14

SARS-CoV-2

0.0030

3b
1a

S4

S2

6 7b 9b 10
7a 9a

hel

nsp4
nsp6 nsp10
nsp8

0.0020

E

ExoN
EndoR

S8

S6

S16
S14

S12

S10

S1

S3

S5

S7

S11

S13

20000

25000

S9

S17

0.0015
S15

Nucleotide diversity

nsp2

3a

2'-O-MTase
RdRp

nsp3

0.0025

N

1b

nsp9
nsp5 nsp7

nsp1

8
M

S

0.0010

0.0005

0.0000
0

5000

10000

15000

Position in alignment

30000

Groups
1
50000

2
3
4

40000

5
6

S16

7
30000

20000

S8
S6

10000
S2
S12
S17 S9

0
S13 S5
S11

-10000

S15

S3

S10
S7

S1

S4

S14

-20000

-10000

0

10000

20000

30000

40000

was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.

I [N=132]

II [N=122]

IV [N=91]
V [N=74]
VI [N=58]
VII [N=3]

oV
hC

III [N=101]

hC
hC oV
o
19
h V
hC Co 19 Sc
oV V 1 US otla
19 9 U A N nd
E
S
Y
L
hC
hC MT ux A W NY DB
e
hC oV 19
oV
U 00
m
A
hC
19
1 27 bo U MC 3
h oV
19 9 F 65.1 urg W1 2 202
Ne oV Co
2
V
8
ra
0
th
er 19 L 19 Fra nc PC Lux 6 2 020 EP
lan
ith Fr nce e N 00 1 2 02
0 EP I IS
a
h
d
u
h
1
1
C
n
s
C
a
hC
E I
0 02
L
6
c H
oV oV 1 oV Haa nia e P F19 20 1P 0 E PI ISL 41
C
2
h
P IS 4 5
L
9
r
19 9 B 19
B lem hVir 164 5 2 020 um I IS L 4 16 640
an L 1 83
02
hC Eng elgiu raz
13 16 3
hC
E
oV lan
32 20 0 E PI 20 41 672 0
oV
m il S 6
4
P IS 2 3
19 d S VA PB 368
20 20
19
8
EP I IS L 4 0 U 593
R
G
H
U
S hCo
2 20
hC
hC aud V 1 SA W EF B 030 06 2 020 EP I IS L 4 146 SA
iA
1
oV
9
o
0
F
h
EP I IS L 4 146 24
19 CoV V 19 rab Wa A UW CC 3 20 20
EP I IS L 4 146 38
le
0
2
Ne
D ia
1
the 9 B enm SCD s PH 191 202 0 EP I IS L 4 167 25
1
0
4
e
2
L
rla
W
lgiu ark C
h
1 02 EP I IS 4 35 1
hC
n
3
oV CoV ds Z m U SS 321 202 0 E I IS L 4 140 72
PI
19
uid
L 15 15
19
LG I 10 20 0
hC Sw Ge Holl 69 1 2 20 EPI ISL 416 155
o
hC oV 1 itzerl rgia and 39 2 020 EPI ISL 416 731
oV
9 G an
31 02 EP ISL 41 729
d Tb
3
0
1
I
h
2
e
hC CoV 9 US org AG0 273 020 EPI ISL 416 555
oV
A W ia T 36 202 EP IS 41 521
19
1
hC 19 B Geo A U b 71 20 0 E I IS L 41 5646
P
20
7
L
oV
e
2
rg
W
19 lgium ia T 136 202 EP I ISL 415 020
5
0
I
b
US
4
A W SH 0 673 2020 EPI ISL 164 35
A U 301 202 EP ISL 413 79
W1 4 20 0 E I IS 41 999
6
L
PI
15
20
IS 41 481
20
20 EPI IS L 4 667
1
4
EP
6
I IS L 41 478
L 4 515
6
16
65
3

hCoV 19 Netherlands ZuidHolland 17 2020 EPI ISL 414559
hCoV 19 France HF1993 2020 EPI ISL 414637
hCoV 19 Denmark SSI 104 2020 EPI ISL 415648
hCoV 19 Netherlands NA 24 2020
EPI ISL 415481
hCoV 19 France HF1870
2020 EPI ISL 414629
hCoV 19 USA WA UW82
2020 EPI ISL 416438
hCoV 19 France HF2039
2020 EPI ISL 415649
hCoV 19 USA WA
UW110 2020 EPI
ISL 416648
hCoV 19 Franc
e B2346 2020
EPI ISL 41651
hCoV 19 USA
0
WA UW73 2020
hCoV 19 Denm
EPI ISL 4156
01
ark SSI 04
2020 EPI ISL
hCoV 19 Belg
416153
ium DB 0302
hCoV 19
3 2020 EPI
France GE1
ISL 416470
973 2020
hCoV 19
EPI ISL 414
France Cler
631
hCoV 19
mont Ferr
and 651
France HF1
2020 EPI
hCoV 19
795 202
ISL 416751
0 EPI ISL
Netherland
hCoV 19
414627
s NA 17
France
2020 EPI
B2351
hCoV 19
ISL 415
2020 EP
473
USA CA
I ISL 416
hCoV
MG098
19 US
513
7 2020
A WA
hCoV
EPI ISL
UW69
19 US
416
202
457
A WA
0 EPI
hCoV
UW
ISL 415
19 Fin
597
land FIN 160 2020 EP
hCoV
I ISL 41
19 Be
030320
lgium
6698
hCoV
20C 20
DBA 03
19 Ne
20 EP
032 20
therla
hCoV
I ISL 41
nds
20 EP
19 Me
3604
I ISL
hCoV
xico CD Utrecht 1
416475
19 Ne
2020
hCoV
EPI IS
therla MX InDRE
L 4144
19 Be
nds NA
01 20
hCoV
35
lgium
20 EP
12 20
I ISL
20 EP
hCoV 19 Nether ULG 6216
4129
I ISL
72
lan
19
20
41
ds
20 EP
Engl
5468
hCoV
NA 25
an
I ISL
2020
4170
hCoV 19 New d 200990
EPI
14
Zeal
723
ISL 41
and
hCoV 19 Braz
5482
20VR 2020 EP
il
I ISL
0189
hCoV 19 Belg SPBR
4140
08 20
ium
2020
12
hCoV 19 Sw
20 EP
DBD
EPI
itz
ISL
hCoV 19 Sw erland 03024 20 I ISL 41
4165
itz
TI20
6029
19
20 EP
hCoV 19 Bel erland
45
I ISL
gi
AG71 2020
4164
hCoV 19 Net um U
EPI
20
LG
71
ISL
3000 2020
4157
hCoV 19 N herland
EPI
et
03
ISL
hCoV 19 N herland s NA 19 2020 E
41
P
et
5457
I IS
sN
2020
hCo 19 P herla
L 41
oord
EPI
nd
er
7004
Bra
IS
hC V 19 B u 010 s NA
L 41
o
11 20 bant 3
e
hC V 19 F lgium 2020
2020 5475
20
o
E
EP
hC V 19 rance ULG 6 PI ISL EPI IS
P
o
Vale
45
L 41 I ISL 41
4157
hC V 19 ortug
5467
nce 7 202
4429
a
o
S
0 E 87
425
hC V 19 witze l CV6
PI
2
o
2
rl
D
hC V 19 enm and G 2020 020 E ISL 41
ark
oV
P
Ne
7
E
E
I
01
P
810
ISL
hC
the
19
SS
o
2 2 I ISL 4
rl
416 5
hC V 19 Nethe ands I 05 2
020
1
7
46
0
o
EP 3647
hC V 19 Switz rland ZuidH 20 E
I IS
P
s
oV
e
B
o
I IS
L4
Utr
elg rlan
hC
1
L4
ec lland
d
iu
o 19
161 5458
28
hC V 19 Belg m G GE1 ht 13
2
4
iu
hC oV 1 Neth m B MH 0 402 2 2020 020 E 0
9
3
hC oV 1 Neth erlan C 03 022 020 E EPI IS PI ISL
9
0
4
L4
hC oV 1 Belg erla ds N 16 2 2020 PI IS
145 1 553
n
A2
9
L
0
E
2
52
hC oV 1 Be ium ds Z
20 20 EP PI IS 4157
lg
9
u
M
o
2
00
L4
I IS
TR idH
0E
hC V 1 Ne ium
1
o
hC oV 1 9 Bra therl ULG 030 lland PI IS L 415 6468
a
2
hC oV 1 9 Ne zil S nds 694 1 20 13 2 L 415 157
2
2
U
o
P
9
th
4
0
0E
7
2
2
hC V 1 Sw erl BR tre
ch 020
PI 0 EP 6
hC oV 1 9 H itze ands 03
t
E
IS
I
1
IS
PI
2
u
hC oV 9 N nga rland No 020 5 20
ISL L 416 L 41
1
o
20
46
44
41
hC oV 9 F ethe ry 4 BE rdB EPI
E
7
70
7
1
hC oV 9 S inlan rlan 9 20 6651 raba ISL PI IS 021
d
hC oV 19 N witz d F s N 20 E 202 nt 36 4140 L 41
IN
45
o
PI
14
0E
2
hC oV 19 F eth erla
54
31 ord
IS
PI 020
hC oV 19 S inla erlan nd G 3 2 Holl L 4
IS
EP
1
0
a
n
L
1
R
o
d
6
w
I
2
n
hC V 9 D it d F s
41
IS
2
0
d 2 74
L4
54
4
en zerl IN Noo 988 EP
hC oV 19
2
5
1
I
0
a
C
5
6
m
2
45
hil
hC oV 19
ark nd 08 tdorp 020 ISL 20 E
45
PI
hC oV 19 Belg e S
S GE 202
13 EP 414
hC oV 19 Sw ium anti SI 0 142 0 E 642 I IS 641 ISL
41
L4
hC oV 19 Ne itze
M ago 1 2 2 20 PI IS 22
45
49
L 4 202 156
hC oV 19 Be the rlan TR 2 2 020 20
hC oV 19 Ne lgiu rlan d 1 030 020 EP EPI 146 0 E 98
43 PI IS
IS
EP I IS
hC oV 19 US the m Q ds Z 000 26
L
L
L4
KJ uid 47 202 I IS
41
hC oV 19 En A rla
4
13
hC oV 19 N gla WA nds 03 Ho 779 0 E L 4 161 545
57
14 42
4
oV 19 B eth nd UW Ro 01 llan 7 2 PI
9
5
5
0
19 U elgiu erla SH 15 tter
20 d 2 20 ISL 80
Br SA m nds EF 9 2 dam 20 0 2 EP 416
02
I
E
az W U
4
B 0
il A U MF NA FC 20 E 136 PI IS 0 E ISL 76
SP W 0 15 B
47
PI 41
P
L
1
BR 1 30 20 2 I IS 40
41 IS 302
3
0
14 8 2 25 2 20 20 L 4 202 515 L 41 3
45
20 02 02 EP EP 166 0 E 8
62
20 0 E 0 E I IS I IS 97
PI
IS
PI L 4 L
EP PI
4
L
I IS ISL ISL 15 16
41
35
4
4 47 730
L
84
41 166 16 1
60 76 47
2
36

hCoV 19 France BFC2094 2020 EPI ISL 415651
hCoV 19 Belgium BM 03012 2020 EPI ISL 415154
hCoV 19 France HF1684 2020 EPI ISL 414626
EPI ISL 416678
hCoV 19 USA WA UW140 2020
28 2020 EPI ISL 415485
hCoV 19 Netherlands NA
2020 EPI ISL 416496
hCoV 19 France HF2237
ISL 416498
IDF2256 2020 EPI
3
hCoV 19 France
EPI ISL 41669
WA UW155 2020
5
hCoV 19 USA
EPI ISL 41552
Holland 3 2020
43
rlands Noord
EPI ISL 4161
hCoV 19 Nethe
02
ark SSI 02 2020
EPI ISL 4165
hCoV 19 Denm
ce B2330 2020
ISL 416434
hCoV 19 Fran
2020 EPI
WA UW78
415487
0 EPI ISL
hCoV 19 USA
NA 30 202
414635
Netherlands
0 EPI ISL
988 202
hCoV 19
416691
France HF1
0 EPI ISL
hCoV 19
153 202
415159
UW
EPI ISL
USA WA
625
91 2020
hCoV 19
I ISL 415
BA 022
Belgium
2020 EP
414648
UW60
hCoV 19
0 EPI ISL
69
USA WA
101P 202 EPI ISL 4164
hCoV 19
A CA PC
2020
417018
19 US
03031
hCoV
EPI ISL
m SN
2020
416672
19 Belgiu ULG 6670
EPI ISL
hCoV
416506
lgium
4 2020
I ISL
19 Be
UW13
09
20 EP
hCoV
4165
A WA
337 20
I ISL
19 US
52
nce B2 4 2020 EP
hCoV
4156
19 Fra
I ISL
48
B234
hCoV
20 EP
4136
ance
I ISL
147 20
19 Fr
49
20 EP
BFC2
4167
hCoV
ance
I ISL
63 20
42
19 Fr
gal CV 2 2020 EP ISL 4156
hCoV
I
05
Portu
53
19
ce
20 EP ISL 4165
hCoV
Valen
7 20
45
I
ance
Tb 47 2020 EP ISL 4144
19 Fr
I
6
orgia
4642
hCoV
B233
19 Ge
20 EP I ISL 41 96
39
hCoV 19 France land 9 20
20 EP I ISL 41 42
ol
5 20
66
hCoV s ZuidH
N 45 2020 EP ISL 41 88
land
d FI
86
ther
EPI
4154
nlan
94
89
19 Ne oV 19 Fi land TI
2020 EPI ISL
4134
104
hCoV
hC
itzer
UW
2020 EPI ISL 416725
19 Sw SA WA NA 31
L
U
s
I IS
2020
5460
hCoV
P
19
41
rland niSR1
25
20 E I ISL
hCoV
U
ethe
P
7 20
4145 60
Italy
19 N
20 E I ISL
W18
66
hCoV hCoV 19 WA U nd 1 20
EP
L 41
41
la
SA
2020 EPI IS 4161 2
19 U s Flevo
081
20
ISL 1547
hCoV rland 201040 122 20 0 EPI
L 4 5629
I IS
02
W
1
ethe land
A U I 09 2 20 EP ISL 4 3602
19 N
Eng
I
AW
SS
20
19
EP ISL 41 6831
hCoV
US
16
ark
20
1
hCoV oV 19
4
enm ds NA 04 20 0 EPI
53
hC
ISL 4151 2
n
9D
0
02
PI
2
V1
erla EDB
E
L
48
d
hCo 9 Neth
20A 2020 PI IS 416 25
tlan 0320
L
1
C3 020 E PI IS 4165 28
3
oV
Sco
2
hC
UM
L
19
IN0
4
E
oV
d F Y NY 3011 020 PI IS 414 27
hC
2
L
lan
0
0
Fin USA N VLM ia Tb 020 E PI IS 414 43
19
m
32
ISL 4155 04
19
0E
org
oV
oV Belgiu 9 Ge 311S 202 EPI
hC
ISL 157 6
hC
1
0
0
1
I
t
U
19
oV
an 5 202 0 EP ISL 4 1356 7
oV
hC an SM Brab
hC
R0 202 EPI ISL 4 1670 9
ord
5
0
CV
Jap
1
I
4
19 ds No tland HL 0 202 0 EP ISL 140 9
9
6
4
I
P
oV
n
rla 9 Sco SA U E253 202 0 EP ISL 4164 95
hC
the
1
2
B
80
U
PI
L
64
Ne
oV
19 rland 3647 9 20 20 E I IS 41 019
19
L
P
hC
7
1
0
oV
e
16
7
oV
hC witz cum UW 21 2 20 E PI IS L 41 445
hC
0
S
1
E I IS 41 633
lari
WA E3 78 2 20
19
B
EP ISL 414 94
2
SA d G
oV
20
ds
hC rlan 19 U rlan IDF2 234 020 EPI ISL 164 01
e
the oV
L 4 146 8
F2 54 2 20
ce
PI
itz
Ne
hC 9 Sw Fran ce H 67 7 20 20 E PI IS L 4 570 3
19
n
G
1
0
9
1
E I IS 41 97
oV
L 12 23
UL ant 0 2 20
Fra
P
oV
V1
hC
hC hCo V 19 ium rab 198 3 20 0 E PI IS L 4 145 2
o
elg ordB IDF 22 202 0 E I IS L 4 463 6
2
hC 9 B
P
1
1
No nce e N 620 202 0 E I IS L 4 401 5
ra
ds
oV
nc
N1 984 202 EP I IS L 41 665 4
0
hC erlan 19 F Fra ce
4
1
n
E4 G1 202 0 EP I IS L 4 61 16
th
1
oV V 19 Fra d G
Ne hC
CD 60 202 0 EP I IS L 4 167 62
n
o
9
P IS 4 54 4
19
2
hC oV 1 erla Italy 906 77
L 1
2
z
9
20 0 E I
oV
9
hC Swit V 19 200 E1 05 202 0 EP I IS L 4 165 26
hC
4
P
G
4
19 hCo land ce PBR 117 202 0 E PI IS L 416 646
2
IS
n
2
4
g
E
3
S
oV
20 20 EPI ISL 41 645 30
UW I 0
En Fra zil
hC
19
19 Bra WA SS 178 20 0
PI ISL 41 46 1
oV oV 19 SA ark UW d 2 202 0 E PI ISL 41 666 97
n
L 1
U nm A
hC hC oV
2 202 0 E PI
9
IS 4 64
rla S
De A W lde 311 bl1 202 0 E PI ISL 41
hC V 1
o
e
L
S
E I
0 m
19
6
02
U
G
U
hC oV
26 6 2 020 EP I IS
M ar y
19 ds
hC oV lan n S ng FIN W9 1 2 020 EP
r
u
0
a
hC the ap 9 H nd A U 187 3 2 02
J
Ne 19 V 1 inla A W HF 12 9 2
o 9F S
e UW 23
19 V
o
hC V 1 9 U anc A
F2
hC
W H
1
o
Fr
hC oV 19 SA nce
hC oV 9 U Fra
1 9
hC V
o V1
hC Co
h

bioRxiv preprint
doi: https://doi.org/10.1101/2020.04.14.040782; this version posted April 20, 2020. The copyright holder for this preprint (which
Subtypes
of SARS-CoV-2

VIII [N=3]
IX [N=2]
X [N=1]
XI [N=1]
XII [N=1]
XIII [N=1]
XIV [N=1]
XV [N=1]

oV

hC

Tree scale: 1

16 82
30 63
41 41 2
L
L
1
I IS I IS 166 99
EP EP L 4 165 91
4
20 20 IS
45 0
20 20 PI ISL 41 57 0
02 80 20 E PI ISL 416 648
0
E
I
BR H0 20 20 EP ISL 41 584
SP i S 645 20 20 PI ISL 416 593
il
a
I
E
0
1
6
2
L
P
2
0
1
3
az gh P0 6
Br an n D P03 22 202 20 E PI IS L 4 166 7
19 Sh pa n D UW 65 20 0 E I IS L 4 650 6
EP I IS 41 656
oV 19 Ja pa WA 00 37 02
68
4
DP Tb 5 00 2 020 EP ISL 41 41
hC oV 19 Ja SA
14
L
2 20 PI
2
an
hC oV 19 U
L4
65
14
0
ia
IS
1
p
0
2
hC oV 19 Ja org DP 031 7 2 20 E PI L 41 166 PI IS
43
16
hC oV 19 Ge pan DP 082 20 20 E I IS
L 4 0 E 82
L4
hC oV 19 Ja an DP 340 20 EP PI IS 202 144
I IS
4
hC oV 19 Jap an B2 027 020 0 E d 8
L 4 59
EP
hC oV 19 Jap nce P0 9 2 202 llan
I IS 416 20
81
P
0
84
hC oV 19 Fra an D KU0 87
Ho 0 E ISL bi 2 72
40
hC oV 19 Jap ait P06 Zuid 202 EPI hori 165 ISL
I
4
w
D ds 23 20
hC oV 19
Alg L 4 EP 098
n
n
Ku
hC oV 19 apa erla iseA 9 20 RC PI IS 020
41
hC oV 19 J eth Cru 031 AIM 0 E 1 2 I ISL 03
K 02
P
P
00
65 87
hC oV 19 N SA
n D rabia 78 2 CQ 20 E L 41
hC V 9 U pa
65
0
0
A
o
1
C
6
a
2
1
IS
0
i
hC oV 9 J aud DP IVD isl EPI ISL 4 658
09
1
5
1
57
4
hC oV 9 S pan qing 051 020 EPI
41
1
ISL
27
hC oV 9 Ja ong IDF 4 2 020
ISL
91
55
PI
3
I
5
1
h
4
hC oV 1 9 C nce B23 78 2 20 E 0 EP 416
0
ISL
hC oV 1 9 Fra nce P02 74 2 202 I ISL EPI
hC oV 1 9 Fra an D P02 U 01 0 EP 020
1
p
2
2
92
45
hC oV 1 9 Ja an D u ZJ 0 20 t 18
A
65
14
o
29 trech 0 BR L 41 8430 ISL 4
hC oV 1 9 Jap gzh
2
0
P0
IS
n
PI
hC oV 1 Ha an D ds U n 20 EPI ISL 4
0E
a
9
n
02
hC oV 1 Jap erla hum 2020 EPI
6 2 6578
0
19
eth 02
nt
94
hC
02
1
a
V
2
2
4
b
o
0
SP
9N
hC oV 1 08.1 n DP 0515 rdBra I ISL 988
373 8482
P
F
7
hC 1268 Japa e ID s Noo 20 E L 40 L 416
40
0
IS
19 ranc and
ISL
I IS
MT
22
PI
I
P
5
F
E
P
E
oV
1
erl
0 E 6723
hC V 19 Neth DP0 2020 2020
o
202
n
41
558
hC V 19 Japa ore 3 0070
001 I ISL
414
82
p
o
165 PI ISL
hC V 19 inga hai SH C SD 0 EP
S
L4
D
2
o
hC V 19 hang ng IV 85 20 EPI IS 020 E 20
2
S
o
o
45
W1 2020
16
hC V 19 hand
L 41
nd
AU
S
o
1
I IS
P
hC V 19 SA W P019 idHolla
6625
0E
o
U
D
Zu
202 I ISL 41
hC V 19
pan
nds
6617
at2
o
EP
hC V 19 Ja etherla BavP
L 41
20
y
I IS
o
6607
hC V 19 N man 0765 20 20 EP
L 41
er
79
P
I IS
hCo 19 G pan D
99 20 20 EP
4165
69
ISL
83
20
DP06
hCoV 19 Ja
EPI
4165 ISL 4129
pan P0543
2020 EPI ISL
D
hCoV 19 Ja
EPI
pan P0158
20
2020
D
hCoV 19 Ja
21
027
96 20
pan
4166
hCoV 19 Ja n DP01 Kng 19
I ISL
5631
P
03
EP
pa
41
hCoV 19 Ja n Hu D 3 2020
4136
I ISL
I ISL
20 EP
hCoV 19 Japa n DP074
20 EP
14
10 20
0B 20
4144
hCoV 19 Japa nd CVR
3202
I ISL
la
6620
hCoV 19 Scot d FIN030 2020 EP
L 41
LD09 20 EPI IS
hCoV 19 Finlan
5539
lia Q
5741
ISL 41
24 20
I
hCoV 19 Austra
ISL 41
I
DP07
20 EP
20 EP
hCoV 19 Japan HL 01 20
75
03 20
L 4166
CGU
A UP
hCoV
EPI IS 6585
19 US an CGMH
7 2020
iw
L 41
hCoV
UW13 20 EPI IS
19 Ta
A WA
20
hCoV
416542
19 US n DP0236
I ISL
hCoV
20 EP
pa
413025
17 20
19 Ja
EPI ISL
416733
hCoV
wait KU
1 2020
EPI ISL
19 Ku
3 UW
E 2020
hCoV
6407
A WA
BFCE
I ISL 41
19 US
SHEF
20 EP
hCoV
gland
0126 20
416571
19 En
hCoV
ghai SH
0 EPI ISL
214
19 Shan
0077 202 0 EPI ISL 413
hCoV
an DP
7 202
975
19 Jap
hCoV
I ISL 412
ia NSW0
Austral
2020 EP
NSW05
hCoV 19
412974
Australia
EPI ISL
hCoV 19
1 2020
ISL 416331
Italy SPL
2020 EPI
hCoV 19
SH0022
ISL 416601
Shanghai
EPI
hCoV 19
457 2020
ISL 415581
Japan DP0
1 2020 EPI
hCoV 19
ada BC 0242
416603
hCoV 19 Can
2020 EPI ISL
n DP0464
413213
hCoV 19 Japa
2020 EPI ISL
2
alia NSW06
EPI ISL 41551
hCoV 19 Austr
Brabant 56 2020
rlands Noord
1
hCoV 19 Nethe
EPI ISL 41549
lands NA 34 2020
hCoV 19 Nether
2020 EPI ISL 416598
hCoV 19 Japan DP0357
2020 EPI ISL 416609
hCoV 19 Japan DP0568
2020 EPI ISL 416706
hCoV 19 USA WA UW168
EPI ISL 416633
hCoV 19 Japan DP0880 2020
hCoV 19 Japan DP0346 2020 EPI ISL 416597
hCoV 19 Japan DP0059 2020 EPI ISL 416569
hCoV 19 Belgium ULG 6638 2020 EPI ISL 417017

hC
hC oV
oV 19
S
19 19 ich
hC Ne Vie ua
tn n IV
oV w
hC 1 Ze am
D
oV 9 S ala VR C S
hC
0
C
hC
1 ha nd
oV
oV hC 9 A ng 20 3 38 00
19
h
19 oV ustr hai VR 14 1 2
hC
Gu
h C
0
oV
an Co oV 1 Ja 19 alia SH0 27 2 2 020
0
gd V 1 9 pa
19
B
0 6
US n T eij QLD 21 20 20 EPI
on
9
Gu
Ja
g
Y ing
20 20 EP IS
0
A
an
gd hCo 202 pan WA WK 23 1 2 20 EP I IS L 4
0
hC
hC ong V 1 0XN TY UW 01 3 20 20 EP I IS L 4 084
20 9 C 44 W
1 2 2 20 EP I IS L 4 086 84
hC oV 1 oV
0
I
L 1
19 20X hin 75 K 5 58
9
oV
20 20 EPI ISL 41 65 68
P
S
2
a
S
N
19
he
E
W 00 1
2
h
IS 4 6 39
4
hC Sh nzh ang 459 F0 42 202 0 E PI IS L 4 07 330
0
P
e
h
20 0
e
L 13 89
E I
hC oV 1 nzh n H ai S P00 19
20 20 E PI ISL 408 52 4
en
9
K
oV
4
H
0
19 Sha HK U S 000 1 20 20 E PI ISL 416 665
Z
IS 40 69
4
ng
U
20
S
P
h
0
2
h
C
h
05
02 E I IS L 4 86 6
an hai SZ
hC CoV oV
P
19 hCo gha SH 002 202 0 E I IS L 4 138 67
oV
1
19 9 So Sha V 19 i SH 012 20 0 E PI IS L 4 137 54
13 49
Ne
uth
ng
US 000 8 20 20 E PI
L
h
P ISL 41 85
hC w Ze Kore ai S A T 9 2 20
02 E I IS 40 631 8
X
o
ala
H
hC V 1
nd a KC 005 1 20 0 E PI IS L 4 583 8
9
o
0
hC
hC V 19 Geo 20V DC0 9 20 20 E PI IS L 4 603 9
oV
oV
R
2
rg
P
0
3
L 16
19
19 Fran ia T 027 202 0 EP I IS 41 409
Ne
6
5
L
ce
b
Sp
0
the
GE 390 202 EP I ISL 411 322
ain
rla
h
0
9
I
C
1
hC nds N oV 1 Vale 583 2020 EPI ISL 4163 56
40
oV
6
9 U ncia 20
IS
oo
E
hC
6
PI
L 4 71
20
5
oV
hC 19 F rdBra SA
9
19
ran
IL2 2020 EPI ISL 165 3
oV
hC
b
4
an
Gu
oV
ce
19
ISL 16 38
20
E
t
an
19
gz Wuh GE1 46 2 20 E PI IS 41 477
G
hC uang hou G an W 583 020 PI IS L 41 4623
oV
zho
H0 202 EPI
ZM
L 4 648
hC
oV 19 Sh u GZ U00 4 20 0 EP ISL 100 4
20
42
4
M
4
I
1
a
hC
oV 9 Jap ndon U001 202 EPI ISL 4 1550 5
gL
an
19
0E
62
ISL 146 3
hC
Y
T
S
P
0
00
0
Y
han
4
2
I
oV
gha WK 5 7 20 0 EP ISL 4 0680 0
1
hC
20
I
1
0
i
1
oV 9 Aus
hC
tralia SH011 1 202 EPI ISL 4 4688
19
oV
Ch
ISL 146
0E
5
Q
1
ile
202
9S
6
hC
LD
PI
Sa
oV
0
han
ISL 4149 3
0
19
4
gha ntiago 3 202 EPI
S
ISL 4086 0
0E
1
6
hCo hangh i SH0
032 2020 PI IS 4164 6
ai S
hCoV V 19
L
0
202 EPI
H0
Ch
00
ISL 41071 2
0
19
7
Chi ile Talc 2 202 EPI
4
hCoV hCoV
ISL 1457
na
19
19 W
WF a 1 20 0 EPI
9
416
C
hCoV
hi
00
20
IS
uhan
3
na
29
W
19 S
2020 EPI IS L 416 41
316
outh HBCD F0012
L4
EP
CH
Kor
B 03 2020 E I ISL 14577
hCoV ea KU
hCoV
PI IS 4138
20
MC
09
19
L
19 S
03 20 20 EP
hCoV
I IS 413697
hang USA C
20
L
A
hai
19 S
hCoV
SH00 1 2020 EPI IS 412979
hang
L
19
4135
EP
13
ha
hCoV
Shen
zhen i SH0030 2020 E I ISL 40 13
19 N
et
6034
SZTH
2020 PI ISL
hCoV herland
4163
EPI
s Utre 002 20
19 Sh
ISL
26
20
ch
angh
4163
ai SH t 16 2020 EPI ISL
39
hCoV
hCoV
4065
0026
EPI
19
19 Be
93
ISL
lgium India 1 31 2020 EP
4145
I ISL
hCoV
55
GHB
2020
4163
0302
19 Ch
hCoV
EP
I
35
1 20
ina W
19 Be
20 EP ISL 4135
F002
ijing
23
I ISL
hCoV
8 20
IVDC
20
4079
19 Sh
BJ 00
angh
5 2020 EPI ISL 41 76
hCoV
ai SH
19 Sh
3791
EPI IS
0003
angh
L
2020
hCoV
ai SH
EPI IS 408485
0010
19 Br
L
azil AM
2020
hCoV
EPI IS 416317
19 Sh
BR 02
L 4163
anghai
2020
hCoV
EPI ISL
SH00
23
19 Au
74
41
20
hCoV
stralia
70
20 EP
19 Wu
VIC07
I ISL 41 34
han HB
20
63
20
CD
77
hCoV 19
EPI ISL
C HB
02
416415
Germa
ny BavPa 2020 EPI ISL
hCoV 19
412978
t3 2020
Austral
EPI ISL
ia NSW0
hCoV 19
414521
1 2020
Shando
EPI ISL
ng LY005
hCoV 19
407893
Guangd
2020 EPI
ong 20S
ISL 414
F012 202
hCoV 19
938
Shanghai
0 EPI ISL
SH0117
403932
2020 EPI
MT123292.2
IQTC04 hum ISL 416403
hCoV 19 Shan
an 2020 CHN
ghai SH0029
2020 EPI
hCoV 19 Aust
ISL 416338
ralia QLD04
2020 EPI ISL
hCoV 19 China
410718
WF0001 2020
EPI ISL 4136
hCoV 19 China
91
WF0014 2020
EPI ISL 41371
hCoV 19 Englan
1
d 02 2020 EPI
ISL 407073
hCoV 19 Netherlands
Gelderland 1 2020
EPI ISL 415461
hCoV 19 Australia QLD02
2020 EPI ISL 407896
hCoV 19 Wuhan HBCDC
HB 04 2020 EPI ISL 412980
hCoV 19 Vietnam CM99 2020 EPI
ISL 416429
hCoV 19 South Korea KUMC01 2020 EPI ISL
413017
hCoV 19 Scotland CVR07 2020 EPI ISL 415630
hCoV 19 USA WA UW108 2020 EPI ISL 416646

XVI [N=1]

hC
hCoV oV 19 U
SA
19 U
WA
hCoV
SA
S40
WA
19 U
2020
UW
SA
hCoV
10
E
19 U WA UW 6 2020 PI ISL
hCoV
SA W
126
4170
E
2020 PI ISL
A
93
19 U
4166
SA W UW85
EPI
hCoV
2020
ISL
44
19 US A UW95
4166
EP
hCoV
20
A
W
20 EP I ISL 41 64
19 US
A S1
64
hCoV
1 20
A
I
20 EP ISL 4164 41
19 US WA UW
57 20
I
51
A WA
20 EP ISL 4164
hCoV
UW68
66
I ISL
19
hCoV
2020
19 US USA WA2
EPI IS 415622
A WA
2020
hCoV
L
UW15
EPI IS 415596
19 US
A WA4
2020
L
hCoV
EPI IS 412970
19 US
UW2
L
A WA
2020
hCoV
UW19
EPI IS 414363
19 US
0 2020
L 4134
A WA
hCoV
EP
UW
55
I
18
ISL
19 US
8 2020
416728
A WA
EPI ISL
hCoV
UW59
19 US
416726
2020
A WA
EPI ISL
hCoV
UW
19 US
415624
A WA UW 89 2020 EP
hCoV 19
I ISL
145 202
USA WA
0 EPI ISL 416445
UW127
hCoV 19
416683
2020 EP
USA WA
I
ISL
UW
hCoV 19
124 202
416665
0 EPI ISL
USA WA
UW26 202
416662
hCoV 19
0 EPI ISL
USA WA
414595
UW92 202
hCoV 19
0 EPI ISL
USA WA
416448
S2 2020
hCoV 19
EPI ISL 413
USA WA7
456
UW4 2020
hCoV 19 USA
EPI
ISL
4134
WA UW179
58
2020 EPI ISL
hCoV 19 USA
416717
WA UW41 2020
EPI ISL 4156
hCoV 19 USA
06
WA UW76 2020
EPI ISL 41560
hCoV 19 USA
4
WA UW80 2020
EPI
ISL 416436
hCoV 19 USA WA
UW152 2020 EPI
ISL
416690
hCoV 19 USA WA UW100
2020 EPI ISL 416638
hCoV 19 USA WA UW156
2020 EPI ISL 416694
hCoV 19 USA WA UW46 2020
EPI ISL 415611
hCoV 19 USA WA UW165 2020 EPI ISL
416703
hCoV 19 USA WA UW50 2020 EPI ISL 415615
hCoV 19 USA UT 00020 2020 EPI ISL 417028
hCoV 19 USA MN3 MDH3 2020 EPI ISL 414590
hCoV 19 USA WA S29 2020 EPI ISL 417082
415619
hCoV 19 USA WA UW54 2020 EPI ISL
ISL 415603
hCoV 19 USA WA UW75 2020 EPI
EPI ISL 415627
hCoV 19 USA WA UW62 2020
2020 EPI ISL 415609
hCoV 19 USA WA UW44
416649
UW111 2020 EPI ISL
hCoV 19 USA WA
ISL 416669
UW131 2020 EPI
6
hCoV 19 USA WA
EPI ISL 41663
WA UW98 2020
416641
hCoV 19 USA
2020 EPI ISL
WA UW103
ISL 416435
hCoV 19 USA
9 2020 EPI
UW7
51
WA
EPI ISL 4166
hCoV 19 USA
94
UW113 2020
WA
4155
ISL
USA
EPI
hCoV 19
UW66 2020
416447
USA WA
0 EPI ISL
hCoV 19
UW91 202
ISL 416667
USA WA
2020 EPI
hCoV 19
096
UW129
ISL 417
USA WA
2020 EPI
433
S43
hCoV 19
416
I ISL
USA WA
2020 EP
598
hCoV 19
UW77
I ISL 415
USA WA
2020 EP
417142
hCoV 19
UW70
EPI ISL
USA WA
9 2020
415602
hCoV 19
A WA S8 2020 EPI ISL
US
19
417121
hCoV
UW74
EPI ISL
6677
USA WA S68 2020
41
19
EPI ISL
42
hCoV
A WA
L 4164
9 2020
19 US
hCoV
UW13
EPI IS 416663
2020
A WA
L
19 US
UW86
EPI IS 416687
hCoV
A WA
5 2020
ISL
56
19 US
UW12 2020 EPI
A
4166
hCoV
W
L
A
149
EPI IS 416439
19 US
L
WA UW 118 2020
hCoV
IS
A
I
11
19 US WA UW
20 EP ISL 4167
hCoV
A
20
83 20
EPI
4156
19 US
WA UW 3 2020
I ISL
hCoV
17
6714
USA
EP
41
19
UW
20
ISL
31
hCoV
A WA
55 20
EPI
4139
19 US A WA UW 6 2020
I ISL
6700
17
hCoV
20 EP I ISL 41 21
19 US WA UW
20
oV
67
hC
SA
UC11 2020 EP ISL 41 27
19 U CDPH
EPI
4167 35
162
hCoV
UC
UW
2020 EPI ISL
USA
WA
4166 23
183
L
19
SA
W
20
U
IS
U
20
71
PI
hCoV oV 19
WA
189
20 E I ISL 41 5595
SA
hC
UW
19 U
41
97 20 20 EP
WA
ISL
6444
hCoV 19 USA WA UW
20
EPI
L 41
A
91
S70
hCoV 19 US A WA 67 2020 EPI IS L 4155 1
S
62
W
hCoV
19 U WA U 88 2020 EPI IS L 415 63
20 PI IS
W
hCoV USA
0
U
135
2
A
E
3
L 4 6668
19
20
AW
W6
I IS
hCoV 19 US WA U 56 20 0 EP ISL 41 710
A
W
I
16
02
hCoV 19 US WA U W8 2 20 EP ISL 4 4618
U
0
V
8
41
PI
SA
hCo 19 U WA12 130 2 20 E I ISL 1668
4
P
W
20
08
A
oV
US WA U 172 020 E I ISL 4156 3
hC
P
19
4
W
2
A
L
oV
US WA U W31 020 E PI IS 4164 28
hC
19
U
0 2 20 E I ISL 4139 7
oV 9 USA WA
5
1
C
h
11
A
L
20
W
1
EP
oV 19 US WA U W43 020 PI IS L 417 637
hC
2
E
8
oV
SA WA U W87 020
I IS 416
hC 19 U
2
EP ISL 1714 6
A
U
9
0
S
oV 19 U A WA
UC 202 EPI ISL 4 1668 2
hC
4
oV 9 US CDPH S64 2020 EPI
65
hC
A
ISL 416 17
1
CA SA W W99 2020 EPI
L 156 3
oV
IS
U
hC USA
1
0
4
5
I
U
19 A WA A S9 202 0 EP I ISL 4167 20
19
V
8
0 5
V
o
2
S
W
4
P
L
o
1
E
A
20
hC 19 U
IS
12
hC
US A UW 114 020 EPI DH 1707 9
V
9
2
o
7
1
M
4
W
hC
A W A U W52 2020 N1 ISL 166 50
oV
M PI
6
hC 9 US
W
L4
A U 175 SA
E
1
IS 416 66
SA
oV 19 U SA W UW .1 U 020 EPI ISL 166 31
C
2
1
h
L 4 170 92
WA 34 22
PI
20
9U
oV
hC oV 1 USA 188 A S 1 20 20 E PI IS L 4 145 5
9
MT A W W14 2 20 0 E PI IS L 4 671 8
hC
2 E
1
1
S
V1
1
IS
0
U
o
U
1
2
I
0
L 4 67 9
A
hC
19
W
UW 128 202 0 EP I IS L 41 670 7
A
oV
SA
W 19 02 EP IS 41 65
0
hC 9 U A W A U
I
6
2
9
L
S W
1
ID 23 020 EP I IS 41 668 8
L 1
2
0
6
oV
LD W
9U A
P
hC oV 1 US lia Q A U 177 202 0 E PI IS L 4 143 78
9
4
2
4
hC V 1 stra A W UW 180 20 0 E PI IS L 408 895
S
o
A
u
W 71 202 0 E I IS L 04 73
hC 19 A 19 U A W A U
1
P
4
W 119 202 0 E PI IS L 4 16 982
S
W
V oV
U
4 2
U
3
IS
o
2
E
2
19 USA WA UW 14
hC hC
20 20 EPI ISL 41 622 N
V
0
A
A
I
L 40 H 0
0
W
9
o
2
S
0
2
P
C
hC oV 1 9 U A W A U UW 01
02 0 E PI IS L 20 848 N
1
E I IS 0 0 H
US A W A YC 1 2 02
hC oV
19 US A W ing WA 8 2 020 EP an 2 L 4 0 C 941
hC oV
S
0
0
2
IS
q
A
9
2
m I
02 14
1 9 U ng
hC oV
US ZJU 06 20 hu EP n 2 L 4
1
ho 9
B
1
1
a
hC CoV 9 C V 1 hou H AZ MS 020 um I IS
h V 1 Co gz DC SA
h EP
2
K
h an BC U
o
.1 03 01 0
H
H 19 610 N 0 an 202
hC
9
n
1
V 26 Y nn 8
a
oV uh hCo T2 DC Yu 00
M IV .1
LY
hC 9 W
1
g
1
an 95 on
oV
nn 49 nd
hC
Yu T0 ha
S
M
19
V
19
o
oV
hC
hC

23
40 97
41 9
89
L 413 02
35
7
I IS L 15
41
L
EP I IS L 4 4
IS
20 EP I IS 603 PI
0
E 62
0
P
2 2 E
41 20
L
68
15 20 20
0
0
6
2
5
IS
4 10
5 9 20 I
57
8
13
L
38
VD E38 17
EP 362 I IS 145 536 073
41
0
4
6
4 06 L 4
P
nd G
L
la nd SZ1 202 t 13 0 E ISL
4 IS
I IS
L
44
er
I
h
2
I
itz erla nd 12 ec 20 EP I IS EP 160 EP
0
P
4
0
2
Sw witz erla BR Utr at1 20
E
2
L
0
19 S witz il SP nds avP 20 020 1 20 I IS 2 2
9 S
1
2 00
36
z
la B
EP 000
oV 1
ra er
H0 1
63
hC oV 19 B eth any i S F21 DC0 020 8 P 31
41 89
hC oV 19 N erm gha 0S ZC 3 2 444 060 ISL 145 61
hC oV 19 G an n 2 H U 0 XN L 4 PI L 4 163
hC oV 19 Sh sha hou ZJ 020 I IS 20 E I IS L 4
hC oV 19 Fo ngz hou g 2 EP 20 EP I IS 957 3
3
12
hC oV 19 Ha ngz don 020 027 020
EP 411 361
02
1
9
hC oV 19 Ha ang 2 2 H0 2 2 020 ISL
L4
12
L4
hC oV 19 Gu an ai S DH 53 2 PI
IS 402 PI IS 87
8
4
L
hC oV 19 Taiw ngh 2 M 00 20 E EPI
E
14 1289
hC oV 19 Sha MN i SH 20 020 PI IS 2019 L 4
9
a
E
IS ISL 4 2
hC oV 19
SA gh H 0 8 2 19
01 PI
6
I
hC oV 19 U han a W iseA 6 20 WH 0 E EP 4163 0
2
2
hC oV 19 S hin Cru IV0 MS
20 2019 ISL 163 3
4
4
hC oV 19 C SA n W BCA 0134 02 EPI
35
51
ISL 416
hC oV 19 U uha n IP R 2
08
HB 020 EPI
7
L4
ISL 422
hC oV 9 W uha CO CDC 54 2 20
I IS
0
PI
1
d
0
hC oV 9 W lan
HB H00 07 2 20 E ISL 4 0 EP
e
2
hC oV 1 9 Ir uhan ai S H00 4 20 EPI
20 920
h
5
20
hC oV 1 9 W ang ai S 004 020
41
13
2
4
hC oV 1 9 Sh angh ai SH 01 2 nvF I ISL 195
3
1
1
65
53
hC oV 1 9 Sh angh WZ HB e 0 EP
L4
40 4
15
g
2
I IS I ISL
L4
hC oV 1 9 Sh jian
84
DC 2 20
EP
P
06 PI IS
e
hC oV 1 Zh han IV W3 020 20 E
L4
E
9
2
H
29
63
20 EPI IS 2020 6
hC oV 1 Wu s P S02
0
120
07
9
138
le
7
136 ISL 4 ISL 4
hC oV 1 Wa gsu J SF2 2020 nd 2
0
9
L4
I
hC oV 1 Jian an 2 IC01 Holla PI IS 0 EP 0 EPI
h
hC V 19 Fos alia V s Zuid 20 E 0 202 8 202 74
0
o
hC V 19 Austr rland A 1 2 2495 P000 4164
0
o
e
L
hC V 19 Neth ruise VB20 20087 PI IS 218
o
C
E
410
hC V 19 USA Kong GD20 020
2
o
ISL 5
09
hC V 19 Hong dong
PI
33
o
JU 020 E 41195
ang ou Z
hC V 19
160
2 2 I ISL
Gu
L4
o
P
I IS
hC V 19 angzh NTU0
58
EP
0E
H
o
4135
an
hC V 19
202 2020 D
ISL
o
Taiw A8
11
IN
EPI
hC V 19 SA C
R
020
20
PB
o
36
hC V 19 U razil S man 2 C2 20
60
32
u
40
U
o
4160
hC V 19 B 29 h DPH PI ISL
15
ISL
.1
C
I
o
36
E
8
P
A
C
9
C
h
0
20
20 E I ISL 41 92
012 USA A2 20
MT
10 20 20 EP L 4136
19 SA C
BR
20
hCoV 19 U zil SP
PI IS 402130
eA 10 20 E
09
ra
L
20
ruis
hCoV 19 B
PI IS ISL 4145
A C F0002
I
19 E
7025
hCoV 19 US
na W
07 20 2020 EP I ISL 41
hCoV 19 Chi an WIV
09
EP
11
W
2020
4164
hCoV 19 Wuh any NR
I ISL
7019
m
24
oV
EP
er
60
LG
U
hC
41
2020
19 G
ium
I ISL
8977
hCoV 19 Belg lia VIC03 20 EP
ISL 40
21
20
ra
EPI
4021
hCoV 19 Aust PHW35
I ISL
2020
47
W03
19 EP
hCoV 19 Wales
L 4160
lia NS
05 20
EPI IS 416390
hCoV 19 Austra IVDC HB
2020
I ISL
uhan
U 06
hCoV
EP
W
ZJ
69
20
19
20
4086
zhou
hCoV
I ISL
Hang ai SH0094
EP
19
20
36
angh
9 20
hCoV
4105
19 Sh n KY V 02
I ISL
6401
hCoV
pa
20 EP
I ISL 41
19 Ja
re 5 20
20 EP
gapo
hCoV
14 20
19 Sin ghai SH01
6 2020
6538
hCoV
an
USA CA
I ISL 40
19 Sh
nCoV
20 EP
hCoV
2019
201 20
M
4258.1 gdong 20SF
2020 VN
an
MT04
an
hum
19 Gu
19 02S
408008
hCoV
nCoV
EPI ISL
773.1
413616
3 2020
MT192
0 EPI ISL
USA CA
202
19
619
11
iseA
hCoV
ISL 413
USA Cru
2020 EPI
hCoV 19
iseA 14
407987
USA Cru
0 EPI ISL
hCoV 19
re 2 202
403962
Singapo
0 EPI ISL
hCoV 19
uri 61 202
ISL 406533
Nonthab
6 2020 EPI
hCoV 19
ou 20SF20
ISL 416321
Guangzh
EPI
19
V
2020
hCo
413559
ghai SH0008
2020 EPI ISL
hCoV 19 Shan
UC3
H
CA CDP
hCoV 19 USA
n 2020 CHN
huma
03
IQTC
5
MT123293.2
EPI ISL 40653
n 20SF210 2020
hCoV 19 Fosha
EPI ISL 406595
en SZTH 004 2020
hCoV 19 Shenzh
416488
P1 2020 EPI ISL
hCoV 19 Poland PL
HB 01 2020 EPI ISL 412459
hCoV 19 Jingzhou HBCDC
0 2020 EPI ISL 417064
VB2001797
case2
Kong
hCoV 19 Hong
hCoV 19 Fujian 13 2020 EPI ISL 411066
hCoV 19 Nepal 61 2020 EPI ISL 410301
hCoV 19 Shanghai SH0055 2020 EPI ISL 416363
hCoV 19 Shanghai SH0121 2020 EPI ISL 416405
hCoV 19 Canada BC 40860 2020 EPI ISL 415583
hCoV 19 Shanghai SH0012 2020 EPI ISL 416325
hCoV 19 Guangdong GD2020080 P0010
2020 EPI ISL 413861
hCoV 19 Guangzhou GZMU0014
2020 EPI ISL 414692
hCoV 19 Jiangsu IVDC
JS 001 2020 EPI ISL 408488
hCoV 19 Shenzhen
SZTH 003 2020 EPI
ISL 406594
hCoV 19 France
IDF0372 isl 2020
EPI ISL 410720
hCoV 19 France
IDF0372 2020
EPI ISL 40659
hCoV 19 Singa
6
pore 1 2020
EPI ISL 40697
hCoV 19 USA
3
CruiseA 6 2020
hCoV 19 Shan
EPI ISL 4136
11
ghai SH0073
hCoV 19
2020 EPI ISL
Wuhan WIV
416376
04 2019 EPI
hCoV 19
China WF0
ISL 402124
003 2020
hCoV 19
EPI ISL 413
USA Cru
iseA 2 202
693
hCoV 19
0 EPI ISL
Jiangsu
413607
JS01 202
hCoV 19
0 EPI ISL
USA Cru
411950
hCoV 19
iseA 7 202
USA Cru
0 EPI ISL
hCoV
iseA 17
413612
19 Ma
2020 EP
laysia
hCoV
I
ISL
MK
413622
19 Gu
AK CL
angdon
2020 504
hCoV
g 20SF
19 Wu
7 2020
014 20
ha
EPI ISL
hCoV
20 EP
19 Wu n WIV05 20
416866
I ISL 40
19 EP
ha
hCoV
3934
I ISL 40
19 Wu n IPBCAMS
2128
MT03
han IPB
WH 05
98
2020
hCoV 87.1 2019 CAMS WH
EPI ISL
19 So
02 20
nCoV
403928
19 EP
hCoV
uth Ko
US
I ISL
19 US
rea SN A WI1 20
40
hCoV
39
20
A
U01
31
19 En CruiseA
2020
MT0
12 20
EPI IS
gland
20
20 EP
L 4119
hCoV 781.2 nC SHEF BF
I ISL
29
oV FI
4136
D54
hCoV 19 USA
2020
17
N 29
CA9
2020 Jan 2020 EPI ISL 41
hCoV 19 Wuh
an IV
EPI
6740
ISL 41
hCoV 19 Net
DC
he
H
B en
2862
hCoV 19 Sing rlands
vF13
Li
ap
21 20
hCoV 19 Wuh ore 7 mburg 7
20 EP
2020
2020
I ISL
hCoV 19 Net an IVD
EP
EPI
CH
4085
he
ISL
B 04 I ISL 41
hCoV 19 Han rland
15
4154
0713
20
64
gzho s NA
hCoV 19 C
6 20 20 EP
u ZJ
hi
I ISL
20 E
U 07
hCoV 19 U na IQT
4021
S
2020 PI ISL
C
hCo 19 Ja A CA5 02 20
4154 20
E
P
20
I IS
95
EP
hCo V 19 S pan TK 2020 E
L
wed
PI IS I ISL 41 416425
V
Y
E
1
hC
6182
9C
en
L 40
2967
o
80
20
hC V 19 C hina IQ 01 202
o
0 E 20 EP 10
hC V 19 ambo TC01
I IS
PI IS
Wu
o
L 41
dia
2
h
hC V 19
001 020 E L 411
o
Ma an W
951 4511
IV0 2 202 PI ISL
lays
hC V 19
o
0
2
J
MT V 19 iangx ia MK 2019 EPI IS 41296
A
159
6
F
i
E
PI IS L 411
hC
71 rance IVDC K CL
o
902
2
L4
JX
IDF
hC V 19 6.1 2
02
00 020
0
0
o
hC V 19 Wuh 19 n 626 2 2 20 5045 127
2
a
C
202
o
hC V 19 Shan n IPB oV U 020 E 0 EP
I IS 0 EP
o
I IS
MT V 19 Wuh ghai CAM SA C PI IS
L4
L
L4
SH
0
S W ruis
hC 1927 Sing an H
168
01
eA 4084 8486
H
B
o
0
7
29
a
3
0
1
CD
7
po
1
hC V 1 2.1
re
C H 202 3 201 8 202
9
0
hC oV 1 Sou nCoV 9 2
9
B 0 0 EP
9
12
I IS EPI IS
19 020
hC oV 1 Gu th K
E
0
L
0
o
L
a
9
1
o
P
1
41
9
40
I
S
hC V 1 Sh ngd rea
63
39
KU hum ISL 4 EPI
97
30
hC oV 1 9 Gu angh ong
IS
M
1
a
0
L4
2
n2
hC oV 1 9 W ang ai SH 0SF C02
02
02 715
d
u
13
hC oV 1 9 H han ong 011 174 2020 0 VN
2
a
M
hC oV 1 9 U ngz WH 20S 0 20 2020 EPI
2
hC oV 9 S SA C hou 01 2 F028 0 E EPI ISL 4
1
13
20 PI IS ISL
hC oV 9 F hang ruis HZ 1 019
01
20
4
L
hC oV 19 S ranc hai eA 4 202 EPI
EP 416 0653 8
1
IS
S
e
39
1
hC oV 9 S inga ID H0 202 0 E
L 4 I IS
9
hC oV 19 N han pore F03 060 0 E PI IS 067 L 40
P
39
hC oV 19 A eth gha 11 73 2 202 I IS L 40 98
36
0E L4
69
0
2
us erla i S
hC oV 19
7
H 02 20
1
tr
hC oV 19 Jap alia nds 010 0 E EP PI IS 360 0
hC oV 19 Jap an D VIC NA 9 2 PI IS I ISL L 4 9
L 4 40 163
04 35 020
hC oV 19 Geo an D P0
67
hC oV 19 Ho rgia P0 287 20 202 EP 107 659
7
hC oV 19 Ne ng K Tb 190 202 20 E 0 E I ISL 19
hC oV 19 Ja the on
46 20 0 E PI PI IS 41
PI ISL
L 4 639
hC oV 19 Ge pan rlan g V 8 2 20
hC oV 19 Ja org DP ds B20 020 EPI ISL 416 154 8
41
41
92
07 NA 02
IS
hC oV 19 Ja pa ia
E
hC oV 19 Ja pa n D Tb 86 21 656 PI IS L 41 658 2
65 9
pa n D P0 54 20 20 5 2 L
oV 1
2
2
4
7
8
9 N
19 Ja eth n D P00 52 202 0 E 0 E 020 156 1
4
E
Ja pa erla P05 37 202 0 E PI IS PI
IS PI 3
pa n D nd 8
20 0 PI
E
IS L 4 L 4 ISL
s 8
n
2
16 15
L
D P08 NA 202 0 E PI
4
1
4
P0 0
6
4
20
P IS
1
0
76 4 2 29
EP I IS L 4 56 28 78
30
4
1
0 2
4
20 20 020 I IS L 41 662 1
20 EP E L 4 65 2
EP I IS PI IS 16 67
61
I IS L
L
0
L 416 415
41 6
48
66 31
6
24

